Zacks Investment Research
28 Jul 2026, 13:50 UTC · 4h ago
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
28 Jul 2026, 13:50 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Kiniksa Pharmaceuticals International (KNSA) reported quarterly revenue of $243.6 million, beating the Zacks Consensus Estimate by 7.09%. — Revenue growth and a beat over estimates generally signal positive operational momentum and demand.
+0.30KNSA's revenue increased from $156.8 million in the prior year to $243.6 million in the current quarter. — Significant year-over-year revenue growth demonstrates scaling of the business.
+0.20KNSA reported quarterly earnings of $0.30 per share, meeting the Zacks Consensus Estimate. — Meeting expectations is a neutral-to-positive signal, providing stability but lacking a catalyst for a significant breakout.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company reported quarterly earnings and revenue that met or surpassed estimates, and its stock has outperformed the S&P 500.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
